ArticleCardiovascular diabetology2023

Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).

Atsushi Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.